Variable (unit)* | Patients with no indication for a statin | Patients with indication for a statin | P value | Patients with indication for a statin and were on a Statin | Patients with indication for a statin and were not on a Statin | P value |
Demographic data | ||||||
No of patients (n) | 565 | 267 | – | 129 | 138 | – |
Age (year) | 38.0 (31.00–44.00) | 51.0 (46.0–57.0) | <0.001 | 51.00 (46.00–58.00) | 51.00 (46.00–56.00) | 0.575 |
Sex, n (% male) | 407 (72.10) | 197 (73.78) | 0.966 | 93 (72.30) | 103 (74.20) | 0.797 |
BMI (kg/m2) | 30.81 (28.16–34.81) | 31.93 (28.25–35.43) | 0.115 | 32.43 (28.70–35.18) | 31.39 (27.50–35.44) | 0.520 |
Liver function test | ||||||
AST (U/L) | 36.00 (28.00–48.25) | 35.5 (28.0–48.0) | 0.520 | 37.00 (28.00–49.00) | 35.00 (27.00–45.00) | 0.339 |
ALT (U/L) | 65.00 (46.00–92.00) | 59.0 (40.00–78.75) | 0.155 | 60.00 (44.00–83.00) | 58.00 (39.00–77.00) | 0.503 |
Total bilirubin (umol/L) | 11(9-16) | 11(9-15) | 0.865 | 11 (9–15) | 11(9-15) | 0.805 |
Albumin (g/L) | 46(44-47) | 45.00 (43.00–47.00) | 0.139 | 45.00 (43.00–47.00) | 45(43-47) | 0.619 |
GGT (U/L) | 51.00 (32.00–88.00) | 58.0 (36.0–114) | 0.004 | 66.0 (36.0–141.0) | 58.00 (38.00–97.50) | 0.240 |
Platelets (109 /L) | 243.0 (207.0–282.8) | 223.0 (192.0–267.0) | 0.001 | 221.5 (188.2–262.0) | 223.0 (192.0–270.00) | 0.534 |
Diabetes profile | ||||||
HBA1C (%) | 5.50 (5.30–5.80) | 6.00 (5.30–7.1) | <0.001 | 6.0 (5.78–6.75) | 6.00 (5.70–6.70) | 0.415 |
Fasting plasma glucose (mmol/L) | 5.20 (4.90–5.60) | 6.00 (5.60–6.70) | <0.001 | 6.2 (5.45–7.10) | 5.90 (5.30–7.20) | 0.187 |
Diabetic classification | ||||||
Diabetes (n) | 40 (7.1%) | 135 (50.6%) | <0.001 | 61 (47.2%) | 74 (53.6%) | 0.202 |
Pre-diabetes (n) | 249 (44.1%) | 88 (32.9%) | – | 44 (31.1%) | 44 (31.9%) | – |
Normal (n) | 276 (48.8%) | 44 (16.5%) | – | 24 (18.6%) | 20 (14.5%) | – |
Lipid profile | ||||||
Total cholesterol (mmol/L) | 5.01 (4.43–5.65) | 4.62 (3.86–5.46) | <0.001 | 4.05 (3.52–4.68) | 5.24 (4.56–5.92) | <0.001 |
HDL (mmol/L) | 1.12 (0.97–1.30) | 1.12 (0.96–1.26) | 0.945 | 1.11 (0.93–1.32) | 1.12 (0.99–1.22) | 0.679 |
LDL (mmol/L) | 3.04 (2.57–3.56) | 2.64 (1.96–3.39) | <0.001 | 2.00 (1.64–2.56) | 3.16 (2.69–3.81) | <0.001 |
Non-HDL cholesterol (mmol/L) | 3.87 (3.30–4.51) | 3.55 (2.75–4.36) | <0.001 | 2.84 (2.36–3.46) | 4.13 (3.57–4.75) | <0.001 |
Non-invasive tests | ||||||
AST/ALT | 0.57 (0.48–0.70) | 0.62 (0.52–0.77) | 0.001 | 0.63 (0.53–0.80) | 0.67 (0.50–0.77) | 0.671 |
AST/√ALT | 4.50 (3.95–5.32) | 4.58 (4.02–5.76) | 0.068 | 4.77 (4.03–5.89) | 4.49 (4.03–5.63) | 0.527 |
FIB-4 | 0.69 (0.52–0.93) | 1.08 (0.80–1.49) | <0.001 | 1.14 (0.83–1.51) | 1.02 (0.80–1.47) | 0.237 |
NFS | −2.89 (-3.50–-2.22) | −1.35 (-2.22–-0.68) | <0.001 | −1.32 (-2.09–-0.58) | −1.62 (-2.38–-0.79) | 0.323 |
Hepamet | 0.02 (0.01–0.05) | 0.10 (0.04–0.21) | <0.001 | 0.10 (0.04–0.21) | 0.1 (0.04–0.21) | 0.994 |
VCTE (kPa) | 5.20 (4.30–6.10) | 5.80 (4.55–7.35) | <0.001 | 5.90 (4.60–7.90) | 5.45 (4.50–6.80) | 0.237 |
Fibrosis prevalence | ||||||
VCTE ≥8 | 50 (9%) | 54 (20%) | – | 32 (25%) | 22 (16%) | – |
VCTE ≥10 | 31 (5%) | 40 (15%) | – | 21 (16%) | 19 (14%) | – |
VCTE ≥12 | 17 (3%) | 27 (10%) | – | 17 (13%) | 10 (7%) | – |
VCTE ≥16 | 8 (1%) | 12 (4%) | – | 9 (7%) | 4 (3%) | – |
*P value correspond to univariable. Results present in median (IQR) or in frequencies (%). AST/vALT: ratio of aspartate aminotransferase to the square root of alanine aminotransferase. HDL: high density lipoprotein cholesterol. LDL: low density lipoprotein cholesterol. HBA1c : hemoglobin A1c. GGT: gamma-glutamyl transferase.
BMI, body mass index; NFS, NAFLD Fibrosis Score; VCTE, vibration controlled transient elastography.